The Pharmacokinetic, Pharmacodynamic And Pharmacogenomic Outcomes Of Reduced Dosage Of Efavirenz: The Encore1 Study
Funder
National Health and Medical Research Council
Funding Amount
$1,234,943.00
Summary
Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.
A Safety, Tolerability, Pharmacokinetic And Efficacy Study Of Azithromycin Plus Piperaquine As Intermittent Presumptive Treatment In Pregnant Papua New Guinean Women
Funder
National Health and Medical Research Council
Funding Amount
$345,684.00
Summary
The purpose of this research is to investigate a new antimalarial combination therapy, azithromycin (AZI) plus piperaquine (PQ), for the prevention of malaria infection in pregnant Papua New Guinean women. It is anticipated that these studies will provide sufficient data to determine if AZI-PQ is a suitable alternative treatment option in PNG, and other countries which have similar malaria epidemiology including the presence of drug resistant parasites.